Literature DB >> 18217456

Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.

Jozo Kristek1, Branko Dmitrović, Sven Kurbel, Kata Sakić, Zlatko Krajinović, Valerija Blazicević, Borislav Has, Ksenija Marjanović.   

Abstract

The aim of this paper is to determine similarities and differences between tumor cell subclones in cases of ductal invasive breast carcinoma, and which occupy primary tumor and local axillary lymph metastases. The tumor growth fraction evaluated by Ki-67 was analyzed along with the expression level of estrogen and progesterone receptors, protein p53, proto-oncogene protein bcl-2 and cathepsin D in 60 patients. Metastatic lymph node in axilla has a higher growth fraction of the tumor cells than the primary tumor (p = 0.045), as well as the higher level of bcl-2 overexpression (p = 0.014). No statistically significant difference was found in the presence of immunohistochemically identified estrogen receptors (p = 0.161) and progesterone receptors (p = 0.081) between the primary tumor and the metastatic lymph node in axilla. Likewise, no difference was found between the immunohistochemical evaluation of p53 (p = 0.356) and cathepsin D activity (p = 0.928). A higher growth fraction of the tumor cells and the higher level of bcl-2 overexpression in metastatic tumor cells indicate the more aggressive cell subclones. This study does not support the routine testing of both primary tumor and locoregional metastasis to evaluate the breast cancer hormone receptor status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18217456

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  6 in total

1.  Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.

Authors:  Daphne Gschwantler-Kaulich; Anneliese Fink-Retter; Klaus Czerwenka; Gernot Hudelist; Axel Kaulich; Ernst Kubista; Christian F Singer
Journal:  Tumour Biol       Date:  2010-12-29

2.  Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Authors:  Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-23       Impact factor: 5.911

3.  Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.

Authors:  Patricia S Steeg
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

4.  Genetic dissimilarity between primary colorectal carcinomas and their lymph node metastases: ploidy, p53, bcl-2, and c-myc expression--a pilot study.

Authors:  Khaled Refaat Zalata; Mohamed Farouk Elshal; Abd AlRahman Mohammad Foda; Ashraf Shoma
Journal:  Tumour Biol       Date:  2015-04-04

5.  Heterogeneity of Bcl-2 expression in metastatic breast carcinoma.

Authors:  Andrea Proctor Subhawong; Hind Nassar; Marc K Halushka; Peter B Illei; Russell Vang; Pedram Argani
Journal:  Mod Pathol       Date:  2010-05-21       Impact factor: 7.842

6.  Comparison of hormone receptor status in primary and recurrent breast cancer.

Authors:  Hamid Saeedi Saedi; Mohammad-Reza Ghavam Nasiri; Soodabeh ShahidSales; Ali Taghizadeh; Nama Mohammadian
Journal:  Iran J Cancer Prev       Date:  2012
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.